Merck, Moderna skin cancer vaccine reduces disease’s recurrence, spread in large trial

A personalized mRNA melanoma vaccine developed by Moderna and Merck shows promise in reducing recurrence and spread. Iparraguirre Recio · Moment/Getty A late-stage trial found that a personalized mRNA therapy for melanoma outperformed Keytruda alone on two important measures of…

Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.

The vaccine reportedly thwarted the cancer's return and spread.

A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source:…

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings…